Within the past year, several laboratories have established the relative feasibility of in vivo introduction and expression of virally introduced exogenous reporter gene within the mammalian cochlea. [1] [2] [3] These preliminary studies provide the foundation for the development of clinical treatment of inherited and acquired hearing loss in humans via gene transfer or gene therapy. However, the development of such clinical applications are contingent upon a variety of factors associated with the transduction of cochlear tissues including the route of delivery and inherent properties of the viral vector utilized for gene transfer. The properties of the viral vector considered to be critical are the duration of expression of its integrated transgene as well as its relative safety.
The choice of adeno-associated virus (AAV) in cochlear gene therapy stems from a number of its attributes. AAV is a nonpathogenic, single-stranded DNA parvovirus that has received significant attention for its application as a gene transfection vector. 4 It is incapable of autonomous replication without the aid of a helper virus and is not known to be associated with human disease. Unlike retroviruses, AAV is able to transduce both pre-and post-mitotic cells. This is particularly important as the neurosensory epithelia of the inner ear are post-mitotic. In vivo studies using an AAV vector system have documented transgene expression in well-differentiated postmitotic adult rat striatal neurons and rabbit lung epi- thelial cells. 5, 6 In addition, these studies have demonstrated prolonged expression of the transgene, up to 6 months, without any adverse host response.
The purpose of this study was to characterize further the use of AAV in cochlear gene therapy. Given the importance of stable or long-term transgene expression in exerting a physiological 'change' at the tissue and organ level, this study characterized the duration of the AAV-integrated transgene expression up to 6 months after direct intracochlear infusion of viral vector into the guinea pig cochlea. In addition, the study also assessed the effects of steady intracochlear vector infusion, via cochleostomy, upon the cochlear cytoarchitecture.
Cochleae from groups of four animals each were harvested after 2, 4, 8, 12 and 24 weeks following AAV infusion. Cochleae from two Hartley guinea pigs infused with saline, two infused with AAV containing green fluorescent protein gene (AAV-hrGFP) and two non-operated animals served as negative controls. Radial sections from these cochleae were then assayed for expression of the marker gene, ␤-galactosidase protein, via in situ immunohistochemistry. ␤-Gal transgene expression was observed within the guinea pig (gp) cochleae from 2 to 24 weeks (Figure 1a-d) . Immunoreactivity to ␤-gal was observed throughout the length of the cochlea -from its base to its apex. Some of these stained cochlear tissues included the organ of Corti, spiral ligament, spiral limbus and the spiral ganglia. Within each tissue type, the staining was non-uniform and of varying intensity. The intensity of staining was the strongest in the basal turn of the cochlea and decreased in the subsequent turns towards the apex. The region conspicuously unstained was stria vascularis, the epithelial tissue that forms the lateral 1a 1c 1b Figure 1d ) weeks after cochleostomy. Nevertheless, ␤-gal expression is detectable within these animals. The reduced expression of the transgene was accompanied by inflammation and degeneration in some but not all of the 12 and 24 week animals. Cochlear sections from saline infused, AAV-GFP infused and unoperated animals showed no evidence of ␤-gal expression, as they were devoid of ␤-gal immunoreactivity (data not shown).
The relatively prolonged and persistent expression of ␤-gal within cochlear tissues as seen in this study is consistent with the 6 month duration of AAV-integrated transgene expression in other animal models and different organ systems. 5, 6 The mechanism(s) involved in longterm AAV-mediated transgene expression is complex and is only now being understood. Persistence of AAV within tissues may be due to either its integration within the genome of the transduced cell or its retention as an unintegrated episome. 4, 7, 8 The relative decline of transgene expression seen over a 6 month period suggests a possible loss of the AAV from the cell. Thus, the decline of transgene expression is consistent with an extrachromosomal presence of AAV genome. Additional factors that may limit expression of the transgene include the relative potency of its promoter within the transduced cell as well as the integrity of the transduced cell as determined by the host immune response. Studies have shown a down-regulation of genetic elements associated with particular viral immediate-early promoters, including the CMV promoter.
9,10 Therefore, the observed decline in ␤-gal expression may be a result of using a CMV immediate-early promoter. Alternatively, cellular division or loss may also explain reduction in the expression of the reported gene.
The expression of the reporter transgene in a variety of tissue types within the cochlea observed in this study reflects a broad range of dividing and nondividing cells transduced by the AAV. Relatively high levels of ␤-gal immunoreactivity were observed within the spiral ligament and the spiral limbus while moderate levels of immunoreactivity were observed within the spiral ganglion and organ of Corti. The highly water impermeable stria vascularis, which plays a critical role in electrolyte maintenance, did not demonstrate ␤-gal expression. The variation in ␤-gal expression within different tissue types may be a function of differential susceptibility of cochlear tissues to AAV transduction and/or differential expression of transgene within the tissues. For example, the difference in degree of transgene expression between the spiral ligament and spiral limbus versus the spiral ganglion and organ of Corti may reflect the mitotic activity of the transduced cells. Thus, the mitotic cells of the spiral limbus may be more susceptible to stable integration of the AAV vector relative to the highly differentiated, post-mitotic neuroepithelia of the organ of Corti and the spiral ganglion, 7,11 yielding a greater and/or more stable expression of the transgene.
The phenomenon of greater transgene expression at the site of AAV vector administration which has been well documented in the brain and the eye was also noted in the cochlea.
6,12 ␤-Gal expression was generally greater at the basilar turn of the cochlea (site of infusion) relative to the more distal apical turn. This regional selectivity is likely the consequence of the viral gradient generated by its localized infusion and subsequent dissemination in the perilymphatic and endolymphatic space. The regional 'spread' or distribution of the virus within the cochlea, not only from base to apex, but also to structures located centrally within the bony modiolous such as the spiral ganglion, is likely facilitated by the radial and longitudinal circulation of the perilymph within the scala tympani and scala vestibuli. In addition, the small diameter of AAV of approximately 11-20 nm may also aid the virus to traverse cochlear tissues through their extracellular space.
Expression of the transgene was also detected within the contralateral cochlea and with a lower level of intensity than that observed within the ipsilateral cochlea. As with the ipsilateral cochlea, analysis of the contralateral cochlea from AAV ␤-gal-infused animals also showed this trend of decreasing immunoreactivity with time with some animals demonstrating transgene expression at 12 and 24 weeks. Expression of the AAV-integrated transgene within the contralateral ear has also been documented using the green fluorescent protein (GFP) as the reporter gene. 13 A possible migratory route to the contralateral ear may be via the cerebrospinal fluid (CSF) since the perilymphatic space into which the virus is infused is directly connected to the CSF via the cochlear aqueduct. Alternatively, the appearance of the virus distant from the site of infusion may be due to its hematogenous dissemination via circulating blood or the bone marrow of the inner ear. Dissemination to distant tissues such as the contralateral cochlea may be mitigated by the delivery of the virus by a single injection in place of a continuous infusion; however, this approach will necessarily sacrifice the even distribution of the virus throughout the cochlea. Further studies will be required to determine the route of viral spread and evaluate possible safety issues concerning direct cochlear infusion with AAV vector as a gene delivery system.
A potential disadvantage of introduction of viral vectors within the cochlea is an ensuing inflammatory response, including labyrinthitis, resulting in irreversible destruction of sensory and neural tissue. Analysis of the cochleae from AAV-infused animals revealed a relatively intact cochlear cytoarchitecture within most animals, including animals killed 6 months after cochleostomy, with the exception of limited localized trauma at the site of surgical cochleostomy. However, several degenerative changes were observed in the tissue architecture in approximately a quarter of the sample group killed at 12 and 24 weeks. These alterations of increasing severity include loose or detached connective tissue, fibrosis and inflammation (Figure 2a) , ossification (Figure 2b) , atrophy of the stria vascularis and cellular degeneration of neuroepithelia (Figure 2b ). This cellular degradation was more evident in the animals killed at 24 weeks. All animals including controls showed evidence of localized fibrosis at the site of the catheter, in the scala tympani of the basal turn of the cochlea. It is unlikely that these changes were secondary to AAV-induced host immune response as relatively few of the animals demonstrated these findings. The intact cochlear cytoarchitecture of all contralateral cochleae further support the absence of recombinant AAV-induced host immune response; contralateral cochleae, harvested 2-24 weeks after AAV ␤-gal infusion, expressing the transgene product were free of changes associated with fibrosis and inflammation that was observed within some of the ipsilateral cochleae. The relative absence of a virus-mediated inflammatory response can be directly attributed to the inability of AAV to go through a replicative and lytic cycle without the co-infection of a helper virus (adenovirus or herpesvirus). Changes seen in the basal turn of the 2a 2b cochlea, within the scala as well as in the neuroepithelia, with preservation of the more apical turns of the cochlea, most likely resulted from localized surgical trauma with insertion of the polyethylene tubing used for infusion of the virus. The more extensive cochlear degeneration associated with osteoneogenesis seen in few of the long-term (Ͼ12 weeks) animals is likely the consequence of bacterial labyrinthitis resulting from middle ear infection or an inflammatory response to surgical trauma. The findings of inflammation and cellular degeneration in some of the animals diminishes some of the enthusiasm for cochleostomy mediated cochlear introduction of the transfecting agent, especially if the consequences of surgical trauma or middle ear infection cannot be minimized.
The ability of this AAV vector and delivery system to introduce and express exogenous genes or transgenes into the peripheral auditory system is a critical step forward towards the eventual application of gene therapy for hearing disorders. Progressive forms of deafness such as presbyacusis or some types of hereditary hearing impairment represent excellent targets for cochlear gene therapy.
14 Long-term or continuous expression of a transgene could potentially substitute for a specific gene dysfunction within the cochlea and reverse progressive loss of the affected sensory epithelia. Alternatively, long-term transgene expression may also aid in the treatment of gradually progressing forms of hearing loss (ie noiseinduced and age-related) by delivering protective trophic factor over time potentially to prevent the gradual cell death that occurs in these forms of hearing loss. Availability of neurotrophins to the auditory neurons following hair cell loss from ototoxins (eg aminoglycosides, antineoplastic agents) may promote their survival and thus improve potential benefit from cochlear implantation. In the future, directed therapy to promote hair cell survival or regeneration could potentially be implemented once the appropriate specific factors are identified. The potential of gene transfer to affect change in the cochlea over long periods of time will also prove useful in efforts to achieve definitive treatments for various hereditary nonsyndromic hearing impairments, for which there are currently no effective therapies.
